Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP137 with mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT05546853Phase 1Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of np137 in pancreatic ductal adenocarcinoma (PDAC), sponsored by CHU Grenoble Alpes. Primary endpoint: Proportion of patients experiencing adverse events at 6 months. Started Mar 2023; status: completed.
02
Drugs
np137
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05546853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546853.